Her research focus is on utilizing high-density lipoprotein (HDL) nanoparticles for drug and vaccine delivery. In 2016, she co-founded a company EVOQ Therapeutics (www.evoqtherapeutics.com) focused on the use of HDL nanoparticles for delivery of personalized neoantigen cancer vaccines. Prior to starting her academic career in 2012, Dr. Schwendeman spent 12 years in pharmaceutical industry at Cerenis Therapeutics, Pfizer, and Esperion Therapeutics. She was involved in discovery and translation HDL drugs to Phase II clinical trials. She successfully submitted FDA INDs for seven different products including nanoparticles, liposome, recombinant proteins, peptides and small molecules.